GBI is a cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines.
GBI also offers process development services from proof of concept and preclinical through phase II clinical studies.
GBI senior vice president SooYoung Lee said by collaborating with Rafagen for cell line engineering, GBI can expand capabilities as a biological contract manufacturing organization and offer one-stop shopping.
"This enables our clients to overcome challenging projects by working from their cDNA to develop more high productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes," Lee said.